세계의 레드 바이오테크놀러지 시장 규모, 점유율, 동향, 산업 분석 리포트 : 제품별, 최종 용도별, 지역별 - 시장 예측(2025-2034년)

The red biotechnology market size is expected to reach USD 1,415.77 billion by 2034, according to a new study by Polaris Market Research. The report "Red Biotechnology Market Size, Share, Trends, Industry Analysis Report By Product (Monoclonal Antibodies, Polyclonal Antibodies, Recombinant Proteins, Vaccines, Cell-Based Immunotherapy Products), By End Use, By Region - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Red biotechnology, a branch of biotechnology, focuses on medical and pharmaceutical applications to improve human health. It involves the use of living organisms, cells, and biological processes to develop therapies, diagnostics, and preventive measures for diseases. This field plays a crucial role in advancing modern medicine, offering innovative solutions for complex health challenges.

One of the primary applications of red biotechnology is in the development of drugs. Researchers produce biopharmaceuticals such as insulin, vaccines, and monoclonal antibodies by leveraging genetic engineering. Recombinant DNA technology enables the production of human insulin using genetically modified bacteria. Similarly, mRNA vaccines and therapeutics, such as those developed for COVID-19, demonstrate how red biotechnology enables rapid responses to pandemics.

Red biotechnology also enhances diagnostic tools and techniques. Advanced techniques, such as polymerase chain reaction (PCR) and next-generation sequencing (NGS), enable the early and accurate detection of diseases, including cancers and infectious diseases. Furthermore, red biotechnology supports vaccine development, which prevents diseases such as hepatitis B, HPV, and influenza. Synthetic biology accelerates vaccine design, while bioreactors facilitate large-scale production. In cancer treatment, immunotherapy, a red biotechnology innovation, harnesses the immune system to target tumors, with therapies such as CAR-T cells showing remarkable success in certain blood cancers.

Red Biotechnology Market Report Highlights

In terms of product, the monoclonal antibodies segment accounted for 49.13% of market revenue share in 2024 due to their widespread adoption in the treatment of cancer, autoimmune disorders, and infectious diseases.

Based on end use, the pharmaceutical & biotechnology companies segment accounted for a major revenue share in 2024 due to their role in driving innovation, clinical development, and commercialization of biologics and advanced therapies.

North America accounted for a 34.16% share of the global red biotechnology market in 2024. This dominance is attributed to established healthcare infrastructure, high R&D investments, and a growing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disorders.

The market in Europe is projected to hold a substantial share by 2034 due to universal healthcare systems, strong government and EU funding, and a focus on regenerative medicine and biosimilars.

The market in Asia Pacific is projected to register a CAGR of 15.34% from 2025 to 2034, owing to increasing healthcare spending, a rising middle class, and a high burden of infectious and noncommunicable diseases.

A few global key players in the red biotechnology market include Amgen Inc.; AstraZeneca; Biogen; Bristol-Myers Squibb Company; F. Hoffmann-La Roche Ltd; Gilead Sciences, Inc.; Merck KGaA; MavriX Bio; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Limited.

Polaris Market Research has segmented the red biotechnology market report on the basis of product, end use, and region:

By Product Outlook (Revenue, USD Billion, 2020-2034)

Monoclonal Antibodies

Polyclonal Antibodies

Recombinant Proteins

Vaccines

Cell-Based Immunotherapy Products

Gene Therapy Products

Cell Therapy Products

Tissue-Engineered Products

Stem Cells

Cell Culture

Viral Vector

Enzymes

Kits and Reagents

Animal Models

Molecular Diagnostics

Other

By End Use Outlook (Revenue, USD Billion, 2020-2034)

Academic Research Institutes

CMOs & CROs

Pharmaceutical & Biotechnology Companies

Others

By Regional Outlook (Revenue, USD Billion, 2020-2034)

North America

U.S.

Canada

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America

Table of Contents

1. Introduction

• 1.1. Report Description
  • 1.1.1. Objectives of the Study
  • 1.1.2. Market Scope
  • 1.1.3. Assumptions
• 1.2. Stakeholders

2. Executive Summary

• 2.1. Market Highlights

3. Research Methodology

• 3.1. Overview
  • 3.1.1. Data Mining
• 3.2. Data Sources
  • 3.2.1. Primary Sources
  • 3.2.2. Secondary Sources

4. Global Red Biotechnology Market Insights

• 4.1. Red Biotechnology Market - Market Snapshot
• 4.2. Red Biotechnology Market Dynamics
  • 4.2.1. Drivers and Opportunities
    • 4.2.1.1. Increasing Demand for Personalized Medicine
    • 4.2.1.2. Rising Investment in Cancer Research
  • 4.2.2. Restraints and Challenges
    • 4.2.2.1. High Cost
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers (Moderate)
  • 4.3.2. Threats of New Entrants: (Low)
  • 4.3.3. Bargaining Power of Buyers (Moderate)
  • 4.3.4. Threat of Substitute (Moderate)
  • 4.3.5. Rivalry among existing firms (High)
• 4.4. PESTEL Analysis
• 4.5. Red Biotechnology Market Trends
• 4.6. Value Chain Analysis

5. Global Red Biotechnology Market, by Product

• 5.1. Key Findings
• 5.2. Introduction
  • 5.2.1. Global Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
• 5.3. Monoclonal Antibodies
  • 5.3.1. Global Red Biotechnology Market, by Monoclonal Antibodies, by Region, 2020-2034 (USD Billion)
• 5.4. Polyclonal Antibodies
  • 5.4.1. Global Red Biotechnology Market, by Polyclonal Antibodies, by Region, 2020-2034 (USD Billion)
• 5.5. Recombinant Proteins
  • 5.5.1. Global Red Biotechnology Market, by Recombinant Proteins, by Region, 2020-2034 (USD Billion)
• 5.6. Vaccines
  • 5.6.1. Global Red Biotechnology Market, by Vaccines, by Region, 2020-2034 (USD Billion)
• 5.7. Cell-Based Immunotherapy Products
  • 5.7.1. Global Red Biotechnology Market, by Cell-Based Immunotherapy Products, by Region, 2020-2034 (USD Billion)
• 5.8. Gene Therapy Products
  • 5.8.1. Global Red Biotechnology Market, by Gene Therapy Products, by Region, 2020-2034 (USD Billion)
• 5.9. Cell Therapy Products
  • 5.9.1. Global Red Biotechnology Market, by Cell Therapy Products, by Region, 2020-2034 (USD Billion)
• 5.10. Tissue-Engineered Products
  • 5.10.1. Global Red Biotechnology Market, by Tissue-Engineered Products, by Region, 2020-2034 (USD Billion)
• 5.11. Stem Cells
  • 5.11.1. Global Red Biotechnology Market, by Stem Cells, by Region, 2020-2034 (USD Billion)
• 5.12. Cell Culture
  • 5.12.1. Global Red Biotechnology Market, by Cell Culture, by Region, 2020-2034 (USD Billion)
• 5.13. Viral Vector
  • 5.13.1. Global Red Biotechnology Market, by Viral Vector, by Region, 2020-2034 (USD Billion)
• 5.14. Enzymes
  • 5.14.1. Global Red Biotechnology Market, by Enzymes, by Region, 2020-2034 (USD Billion)
• 5.15. Kits and Reagents
  • 5.15.1. Global Red Biotechnology Market, by Kits and Reagents, by Region, 2020-2034 (USD Billion)
• 5.16. Animal Models
  • 5.16.1. Global Red Biotechnology Market, by Animal Models, by Region, 2020-2034 (USD Billion)
• 5.17. Molecular Diagnostics
  • 5.17.1. Global Red Biotechnology Market, by Molecular Diagnostics, by Region, 2020-2034 (USD Billion)
• 5.18. Others
  • 5.18.1. Global Red Biotechnology Market, by Others, by Region, 2020-2034 (USD Billion)

6. Global Red Biotechnology Market, by End Use

• 6.1. Key Findings
• 6.2. Introduction
  • 6.2.1. Global Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
• 6.3. Academic Research Institutes
  • 6.3.1. Global Red Biotechnology Market, by Academic Research Institutes, by Region, 2020-2034 (USD Billion)
• 6.4. CMOs & CROs
  • 6.4.1. Global Red Biotechnology Market, by CMOs & CROs, by Region, 2020-2034 (USD Billion)
• 6.5. Pharmaceutical & Biotechnology Companies
  • 6.5.1. Global Red Biotechnology Market, by Pharmaceutical & Biotechnology Companies, by Region, 2020-2034 (USD Billion)
• 6.6. Others
  • 6.6.1. Global Red Biotechnology Market, by Others, by Region, 2020-2034 (USD Billion)

7. Global Red Biotechnology Market, by Geography

• 7.1. Key Findings
• 7.2. Introduction
  • 7.2.1. Red Biotechnology Market Assessment, By Geography, 2020-2034 (USD Billion)
• 7.3. Red Biotechnology Market - North America
  • 7.3.1. North America: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
  • 7.3.2. North America: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • 7.3.3. Red Biotechnology Market - U.S.
    • 7.3.3.1. U.S.: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
    • 7.3.3.2. U.S.: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • 7.3.4. Red Biotechnology Market - Canada
    • 7.3.4.1. Canada: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
    • 7.3.4.2. Canada: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
• 7.4. Red Biotechnology Market - Europe
  • 7.4.1. Europe: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
  • 7.4.2. Europe: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • 7.4.3. Red Biotechnology Market - UK
    • 7.4.3.1. UK: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
    • 7.4.3.2. UK: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • 7.4.4. Red Biotechnology Market - France
    • 7.4.4.1. France: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
    • 7.4.4.2. France: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • 7.4.5. Red Biotechnology Market - Germany
    • 7.4.5.1. Germany: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
    • 7.4.5.2. Germany: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • 7.4.6. Red Biotechnology Market - Italy
    • 7.4.6.1. Italy: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
    • 7.4.6.2. Italy: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • 7.4.7. Red Biotechnology Market - Spain
    • 7.4.7.1. Spain: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
    • 7.4.7.2. Spain: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • 7.4.8. Red Biotechnology Market - Netherlands
    • 7.4.8.1. Netherlands: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
    • 7.4.8.2. Netherlands: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • 7.4.9. Red Biotechnology Market - Russia
    • 7.4.9.1. Russia: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
    • 7.4.9.2. Russia: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • 7.4.10. Red Biotechnology Market - Rest of Europe
    • 7.4.10.1. Rest of Europe: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
    • 7.4.10.2. Rest of Europe: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
• 7.5. Red Biotechnology Market - Asia Pacific
  • 7.5.1. Asia Pacific: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
  • 7.5.2. Asia Pacific: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • 7.5.3. Red Biotechnology Market - China
    • 7.5.3.1. China: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
    • 7.5.3.2. China: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • 7.5.4. Red Biotechnology Market - India
    • 7.5.4.1. India: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
    • 7.5.4.2. India: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • 7.5.5. Red Biotechnology Market - Malaysia
    • 7.5.5.1. Malaysia: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
    • 7.5.5.2. Malaysia: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • 7.5.6. Red Biotechnology Market - Japan
    • 7.5.6.1. Japan: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
    • 7.5.6.2. Japan: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • 7.5.7. Red Biotechnology Market - Indonesia
    • 7.5.7.1. Indonesia: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
    • 7.5.7.2. Indonesia: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • 7.5.8. Red Biotechnology Market - South Korea
    • 7.5.8.1. South Korea: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
    • 7.5.8.2. South Korea: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • 7.5.9. Red Biotechnology Market - Australia
    • 7.5.9.1. Australia: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
    • 7.5.9.2. Australia: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • 7.5.10. Red Biotechnology Market - Rest of Asia Pacific
    • 7.5.10.1. Rest of Asia Pacific: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
    • 7.5.10.2. Rest of Asia Pacific: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
• 7.6. Red Biotechnology Market - Middle East & Africa
  • 7.6.1. Middle East & Africa: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
  • 7.6.2. Middle East & Africa: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • 7.6.3. Red Biotechnology Market - Saudi Arabia
    • 7.6.3.1. Saudi Arabia: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
    • 7.6.3.2. Saudi Arabia: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • 7.6.4. Red Biotechnology Market - UAE
    • 7.6.4.1. UAE: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
    • 7.6.4.2. UAE: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • 7.6.5. Red Biotechnology Market - Israel
    • 7.6.5.1. Israel: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
    • 7.6.5.2. Israel: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • 7.6.6. Red Biotechnology Market - South Africa
    • 7.6.6.1. South Africa: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
    • 7.6.6.2. South Africa: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • 7.6.7. Red Biotechnology Market - Rest of Middle East & Africa
    • 7.6.7.1. Rest of Middle East & Africa: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
    • 7.6.7.2. Rest of Middle East & Africa: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
• 7.7. Red Biotechnology Market - Latin America
  • 7.7.1. Latin America: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
  • 7.7.2. Latin America: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • 7.7.3. Red Biotechnology Market - Mexico
    • 7.7.3.1. Mexico: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
    • 7.7.3.2. Mexico: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • 7.7.4. Red Biotechnology Market - Brazil
    • 7.7.4.1. Brazil: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
    • 7.7.4.2. Brazil: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • 7.7.5. Red Biotechnology Market - Argentina
    • 7.7.5.1. Argentina: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
    • 7.7.5.2. Argentina: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • 7.7.6. Red Biotechnology Market - Rest of Latin America
    • 7.7.6.1. Rest of Latin America: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
    • 7.7.6.2. Rest of Latin America: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)

8. Competitive Landscape

• 8.1. Expansion and Acquisition Analysis
  • 8.1.1. Expansion
  • 8.1.2. Acquisitions
• 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

• 9.1. AstraZeneca
  • 9.1.1. Company Overview
  • 9.1.2. Financial Performance
  • 9.1.3. Product Benchmarking
  • 9.1.4. Recent Development
• 9.2. Amgen Inc.
  • 9.2.1. Company Overview
  • 9.2.2. Financial Performance
  • 9.2.3. Product Benchmarking
  • 9.2.4. Recent Development
• 9.3. Merck & Co
  • 9.3.1. Company Overview
  • 9.3.2. Financial Performance
  • 9.3.3. Product Benchmarking
  • 9.3.4. Recent Development
• 9.4. Bristol-Myers Squibb
  • 9.4.1. Company Overview
  • 9.4.2. Financial Performance
  • 9.4.3. Product Benchmarking
  • 9.4.4. Recent Development
• 9.5. Pfizer
  • 9.5.1. Company Overview
  • 9.5.2. Financial Performance
  • 9.5.3. Product Benchmarking
  • 9.5.4. Recent Development
• 9.6. Biogen
  • 9.6.1. Company Overview
  • 9.6.2. Financial Performance
  • 9.6.3. Product Benchmarking
  • 9.6.4. Recent Development
• 9.7. F. Hoffmann-La Roche Ltd
  • 9.7.1. Company Overview
  • 9.7.2. Financial Performance
  • 9.7.3. Product Benchmarking
  • 9.7.4. Recent Development
• 9.8. Gilead Sciences, Inc.
  • 9.8.1. Company Overview
  • 9.8.2. Financial Performance
  • 9.8.3. Product Benchmarking
  • 9.8.4. Recent Development
• 9.9. MavriX Bio
  • 9.9.1. Company Overview
  • 9.9.2. Financial Performance
  • 9.9.3. Product Benchmarking
  • 9.9.4. Recent Development
• 9.10. Regeneron Pharmaceuticals, Inc.
  • 9.10.1. Company Overview
  • 9.10.2. Financial Performance
  • 9.10.3. Product Benchmarking
  • 9.10.4. Recent Development
• 9.11. Takeda Pharmaceutical Company
  • 9.11.1. Company Overview
  • 9.11.2. Financial Performance
  • 9.11.3. Product Benchmarking
  • 9.11.4. Recent Development